Drugs / BACTEK-R
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04363814 | Jun 2020 → Jan 2022 | COVID-19 | Inmunotek S.L. | Unknown | No outcome recorded |
Press releases naming this drug 18 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BACTEK-R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04363814 ↗ |
| Known as | MV130 | “The purpose of the study is to confirm if BACTEK-R (MV130) provides clinical benefit in subject with mild pneumonia (CURB-65≤2) by COVID-19 admitted to the Hospital.” NCT04363814 ↗ |
| Modality | Other / unclassified | “BACTEK-R is a bacterial preparation that contains a mixture of Gram + and Gram - inactivated bacteria at the concentration of 300 FTU / mL (approx. 10\^9 bacteria / mL)” NCT04363814 ↗ |